Skip to main content

Medistim ASA (MEDI.OL)

66.1Fair

ValueMarkers Composite Index

Top 96%#1,691 of 44,722
Overvalued

57% above intrinsic value ($14)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.32
Low Risk
Altman
2.65
Grey Zone
DCF Value
$14
Overvalued
ROIC
45.6%
Strong
P/E
2.5
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Medistim ASA (MEDI.OL) — VMCI valuation read

Medistim ASA sits at VMCI 66/100, with the broad-market sample median at 50. That 16-point spread is the first thing to note on MEDI.OL: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on MEDI.OL are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on MEDI.OL: MEDI.OL trades at 24.0x earnings, 33% above the sector median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the sector median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of 2.0x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

MEDI.OL fell 3.1% over the trailing 7 days, with a -15.8% read on a 30-day basis.

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.

CEO: Kari Eian Krogstad154 employeesNOwww.medistim.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.